What happened to Schering-Plough in 1983?
1983: Legal conflict begins between Schering-Plough and Schering AG over the use of the Schering name in the United States. 1986: The company appoints Horst Witzel as its first chairman of the board since World War II.
What happened to Schering Schering's US subsidiary?
The company's first U.S. subsidiary was dissolved during World War I. After being reestablished in 1929, it was then seized by the U.S. Alien Property Custodian during World War II. To Schering's chagrin, the subsidiary was eventually sold to private investors and was severed completely from its parent company.
How did Schering expand its business post-war?
A major step in Schering's postwar expansion involved pioneering work in the area of birth control. Using their expertise in steroid research, the company introduced the first birth control pill in the European market in 1961.
See more
How do I find old stock prices?
A web resource for historic stock prices is Yahoo Finance (Stock Prices) - http://finance.yahoo.com/ . Stock prices go back to the 1070s. Begin by doing a search using the ticker symbol, then choose "Historical Prices" from the blue bar on the left; choose daily, weekly, or monthly data.
What happened to Schering Plough stock?
Under the terms of the agreement, Schering-Plough shareholders will receive 0.5767 shares of the newly combined company and $10.50 in cash for each share of Schering-Plough. Each Merck common share will automatically become a common share of the newly combined company.
Why did Merck buy Schering-Plough?
It was within weeks of Hassan's stargazing that Merck began courting Schering-Plough, leading to the Merck takeover in 2009. Merck touted the five stars among other Schering drugs, as well as the deal's potential for big cost cuts. The five stars did make it to market (in the case of Bridion outside the U.S.).
Who bought Schering-Plough?
Merck & Co.FOLLOWING RIVALS Pfizer and Roche down the acquisition trail, Merck & Co. has agreed to pay $41 billion for fellow New Jersey-based drug firm Schering-Plough. The deal, expected to close in the fourth quarter, will create a pharmaceutical behemoth that would have had sales of $46.9 billion last year.